Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

1,274 total articles

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences has begun screening the first patient in its global Phase 3 confirmatory trial of roluperidone, a drug candidate designed to treat negative symptoms of schizophrenia such as avolition, anhedonia, and social withdrawal—symptoms for which there are currently no FDA-approved therapies. The trial plans to enroll approximately 380 …

Tenaris Files its 2025 Annual Report and its Annual Report on Form 20-F

Tenaris Files its 2025 Annual Report and its Annual Report on Form 20-F

Tenaris S.A., a leading global supplier of steel tubes for the energy sector and other industries, filed its 2025 Annual Report with the Luxembourg Stock Exchange and other regulators, including the U.S. SEC. The report includes consolidated financial statements, sustainability information, and auditor certifications. The Form 20-F will be filed wi…

SPAR Group, Inc. Issues Fiscal Year 2026 Financial Guidance

SPAR Group, Inc. Issues Fiscal Year 2026 Financial Guidance

SPAR Group, Inc. announced its financial guidance for fiscal year 2026, projecting net sales between $143 million and $151 million, and gross margins improving to 20.5%-22.5%. The company highlighted a favorable shift towards higher-margin core merchandising services, cost reductions, ongoing AI implementation for efficiency, and recent capital rai…

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Oculis Holding AG announced that the European Medicines Agency granted Priority Medicines (PRIME) designation to its neuroprotective candidate Privosegtor for optic neuritis (ON), following a prior FDA Breakthrough Therapy designation. Supported by positive Phase 2 trial results demonstrating significant improvements in visual function and neuropro…

Workhorse Group Reports Fourth Quarter and Full Year 2025 Results

Workhorse Group Reports Fourth Quarter and Full Year 2025 Results

Workhorse Group Inc. announced its fourth quarter and full year 2025 financial results, marking its first earnings report after merging with Motiv Electric Trucks. The company reported a 64% revenue increase in Q4 and a 201% rise for the full year, driven by vehicle deliveries and product lineup expansion. Workhorse is targeting $20 million in annu…

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

ORIC Pharmaceuticals announced the selection of 400 mg once daily rinzimetostat (ORIC-944) in combination with darolutamide as the recommended Phase 3 dose (RP3D) for the Himalayas-1 global Phase 3 registrational trial in post-abiraterone metastatic castration-resistant prostate cancer (mCRPC). Phase 1b data show favorable safety and promising effi…

TOMI Environmental Solutions, Inc. Reports Full Year 2025 Financial Results and Outlines Growth Initiatives

TOMI Environmental Solutions, Inc. Reports Full Year 2025 Financial Results and Outlines Growth Initiatives

TOMI Environmental Solutions, Inc. announced its financial results for the year ended December 31, 2025. Despite a 27% decline in net sales due primarily to deferred capital expenditures amid economic uncertainty, the company improved its operating loss compared to 2024. TOMI continued to expand its global market presence, secured notable governmen…

Barfresh Announces Fourth Quarter and Full Year 2025 Results

Barfresh Announces Fourth Quarter and Full Year 2025 Results

Barfresh Food Group Inc. announced record revenue for 2025 of $14.2 million, driven by the acquisition of Arps Dairy and expanded school penetration. The company provided optimistic 2026 guidance with expected revenue between $28 million and $32 million, reflecting nearly 100% growth year-over-year. Barfresh secured $7.5 million in convertible note…

Rigetti Announces Novera QPU Sale to the University of Saskatchewan

Rigetti Announces Novera QPU Sale to the University of Saskatchewan

Rigetti Computing announced the sale and shipment of its 9-qubit Novera quantum processing unit (QPU) to the University of Saskatchewan, marking the establishment of USask's first quantum computing system. The system will be managed by the university's Centre for Quantum Topology and its Applications and aims to support innovative research in quant…

nCino Reports Fourth Quarter and Fiscal Year 2026 Financial Results

nCino Reports Fourth Quarter and Fiscal Year 2026 Financial Results

nCino, Inc., a leading provider of intelligent banking solutions, reported strong financial results for the fourth quarter and fiscal year 2026, exceeding all financial guidance metrics. The company achieved record annual contract value (ACV) of $602.4 million, up 17% year-over-year, and a fiscal 2026 ACV net retention rate of 112%. Total revenues …

Brookfield Business Corporation Completes 2025 Annual Filings

Brookfield Business Corporation Completes 2025 Annual Filings

Brookfield Business Corporation has filed its 2025 annual report with the SEC and Canadian securities authorities, including audited financial statements. The company finalized a corporate simplification by exchanging various partnership units for newly issued Class A shares, which will begin trading on the NYSE and TSX under the ticker BBUC starti…

Ellomay Capital Reports Publication of Financial Statements of Dorad Energy Ltd. as of and for the Year Ended December 31, 2025

Ellomay Capital Reports Publication of Financial Statements of Dorad Energy Ltd. as of and for the Year Ended December 31, 2025

Ellomay Capital Ltd. has published the financial statements of Dorad Energy Ltd. for the year ended December 31, 2025. Ellomay holds an indirect 16.9% stake in Dorad through Ellomay Luzon Energy. Dorad reported revenues of approximately NIS 2.65 billion and an operating profit of NIS 385 million for 2025. The results were impacted by seasonal elect…

Data Storage Corporation Postpones 2025 Fiscal Year Conference Call

Data Storage Corporation Postpones 2025 Fiscal Year Conference Call

Data Storage Corporation announced the postponement of its fiscal year 2025 investor conference call to allow more time to complete its year-end audit. The audit complexity stems from significant transactions including the sale of its CloudFirst subsidiary, warrant settlements, and a tender offer. A new date for the earnings call will be announced …

HeartCore Reports Full Year 2025 Results

HeartCore Reports Full Year 2025 Results

HeartCore Enterprises, Inc., a Tokyo-based IPO consulting services company listed on Nasdaq (HTCR), announced its full year 2025 results. The company reported revenues of $9.0 million, gross profit of $3.2 million, and net income of $5.5 million compared to a net loss last year. The positive net income was primarily due to gains from the divestitur…

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics CEO Issues Letter to Shareholders

Cognition Therapeutics announced progress in developing their lead candidate, Zervimesine (CT1812), for neurodegenerative diseases. Positive Phase 2 SHIMMER trial results support advancing the drug to late-stage trials for dementia with Lewy bodies (DLB) psychosis. The ongoing fully funded Phase 2 START trial in mild cognitive impairment and early …